– USA, UT – Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly-owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced the appointment of Dr. Vallerie McLaughlin, MD, to its board as its seventh independent director.
“As Clene continues to advance its clinical pipeline and in particular, as we near the conclusion of the registration trial and potential commercialization of our lead candidate CNM-Au8 for the treatment of ALS, we’re expanding our board with additional independent members and medical key opinion leaders. We are honored to have Dr. McLaughlin join us, and we look forward to benefitting from her expertise.” said Board Chairman, David Matlin.
“A rare disease expert thought leader, and principal investigator in numerous rare disease trials, Dr. McLaughlin’s experience as a leading practicing physician and professor at a top U.S. medical institution will be an asset to Clene,” added CEO, Rob Etherington.
About Dr. Vallerie McLaughlin
Dr. McLaughlin is the Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine, Associate Chief Clinical Officer for Cardiovascular Services of the University of Michigan Medical Group, Associate Chief, Division of Cardiovascular Medicine, and Director of the Pulmonary Hypertension Program at the University of Michigan in Ann Arbor.
Dr. McLaughlin has been the principal investigator of several major clinical trials in pulmonary arterial hypertension, a rare disease, and is widely published in peer-reviewed scientific journals. She is past Editor-in-Chief of Advances in Pulmonary Hypertension and past Chair of the Board of Directors of the Pulmonary Hypertension Association. She is a founding member of the World Symposium on Pulmonary Hypertension Association. Dr. McLaughlin is a Fellow of the American College of Cardiology, American College of Chest Physicians, and American Heart Association.
She received her medical degree from Northwestern University Feinberg School of Medicine in Chicago and completed her internal medicine residency at the University of Michigan Hospitals and cardiology fellowship at Northwestern University.
About Clene
Clene, a clinical-stage biopharmaceutical company focused on neurodegenerative disease treatments, is leading the way by using nanotechnology to treat energetic failure, which underlies many neurological diseases. Clene has innovated a novel nanotherapeutic platform to create a new class of drugs. Clene’s lead drug candidate, CNM-Au8, is an aqueous suspension of catalytically-active, clean-surfaced, faceted gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system. CNM-Au8 increases cellular energy production to accelerate neuro repair and improve neuroprotection. CNM-Au8 is currently being evaluated in a Phase 3 registration trial in amyotrophic lateral sclerosis, a Phase 2 trial examining disease progression via a novel electromyography technique in patients with early ALS, a Phase 2 trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis, and Phase 2 brain target engagement studies in patients with Parkinson’s disease and MS. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The company is based in Salt Lake City, Utah with R&D and manufacturing operations in Maryland.
For more information: https://clene.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.